- G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
- G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
- G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
- G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
- G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
- G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
- G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)
- G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
More ▼
Key statistics
As of last trade G1 Therapeutics Inc (GTHX:NSQ) traded at 3.82, -23.70% below its 52-week high of 5.00, set on Feb 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.93 |
---|---|
High | 3.93 |
Low | 3.81 |
Bid | 3.81 |
Offer | 3.82 |
Previous close | 3.99 |
Average volume | 567.33k |
---|---|
Shares outstanding | 52.20m |
Free float | 46.10m |
P/E (TTM) | -- |
Market cap | 208.28m USD |
EPS (TTM) | -0.953 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 15:53 BST.
More ▼